Pulse Biosciences
3957 Point Eden Way
Hayward
CA
94545
United States
Tel: 833-257-3393
Website: https://www.pulsebiosciences.com/
About Pulse Biosciences
Pulse Biosciences, Inc. is a bioelectric medicine company pursuing commercial introduction of our proprietary CellFX® System initially to the dermatology market. The CellFX System is powered by Nano-Pulse Stimulation™ (NPS™) technology, which delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular skin tissue. The unique cell-specific effects have the potential to significantly benefit patients across multiple medical applications. Designed as a multi-application platform, the initial commercial use of the CellFX System (upon regulatory approval) is expected to address a broad range of dermatologic conditions that share high demand among patients and practitioners for improved and durable aesthetic outcomes.
Stock Symbol: PLSE
154 articles with Pulse Biosciences
-
Pulse Biosciences Schedules Fourth Quarter & Full Year 2022 Financial Results Conference Call for March 30, 2023
3/2/2023
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for electrophysiology and the treatment of atrial fibrillation, announced today it will report financial results for the fourth quarter and full year of 2022 after market close on Thursday, March 30, 2023.
-
Pulse Biosciences Announces Its Novel Nanosecond Pulsed Field Ablation System Will Be Highlighted at the 2023 AF Symposium
2/2/2023
Pulse Biosciences, Inc. today announced its technology will be highlighted in a poster presentation at the 28th Annual International AF Symposium meeting in Boston February 2–4.
-
Pulse Biosciences Reports Third Quarter 2022 Financial Results
11/10/2022
Pulse Biosciences, Inc. today announced financial results for the third quarter ended September 30, 2022.
-
Pulse Biosciences Schedules Third Quarter 2022 Financial Results Conference Call for November 10, 2022
10/27/2022
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report financial results for the third quarter of 2022 after market close on Thursday, November 10, 2022.
-
Pulse Biosciences Announces Positive Clinical Data on Nano-Pulse Stimulation Procedure for Low-Risk Basal Cell Carcinoma Lesions
10/6/2022
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced positive clinical data from an FDA approved Investigational Device Exempt treat and resect study on the use of NPS for low-risk basal cell carcinoma (BCC) lesions.
-
Pulse Biosciences Announces FDA 510(k) Clearance for the Treatment of Sebaceous Hyperplasia
9/26/2022
Pulse Biosciences, Inc. today announced receipt of U.S. Food and Drug Administration (FDA) 510(k) clearance for its CellFX System.
-
Pulse Biosciences Announces Strategic Change of Focus in Support of Significant Additional Opportunities for medicinal related Nano-Pulse Stimulation
9/20/2022
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced a shift in focus to advance its core technology.
-
Pulse Biosciences Reports Second Quarter 2022 Financial Results
8/10/2022
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced financial results for the second quarter ended June 30, 2022.
-
The FDA has had a busy week, accepting drug applications, approving clinical trials and granting various special designations for Gamida Cell, Cellectis, Scynexis & more.
-
Pulse Biosciences Receives FDA 510(k) Clearance of Expanded Energy Settings for use with the CellFX® System
8/4/2022
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced receipt of U.S. Food and Drug Administration (FDA) 510(k) clearance of expanded energy settings for use with the family of CellFX System treatments tips in dermatology.
-
Pulse Biosciences Schedules Second Quarter 2022 Financial Results Conference Call for August 10, 2022
7/27/2022
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report financial results for the second quarter of 2022 after market close on Wednesday, August 10, 2022.
-
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 16, 2022
6/16/2022
Pulse Biosciences, Inc. announced that the Compensation Committee of its Board of Directors has granted equity awards to three new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Equity Incentive Plan.
-
Pulse Biosciences, Inc. Announces the Closing of Its Rights Offering
6/9/2022
Pulse Biosciences, Inc., a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ technology, announced the closing of its rights offering and the final results thereof.
-
Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering
6/3/2022
Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, announced today preliminary results of its rights offering, which expired at 5:00 p.m., Eastern Time, on May 26, 2022.
-
Pulse Biosciences, Inc. Announces Changes to its Rights Offering
5/19/2022
Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company commercializing the CellFX® System Powered by Nano-Pulse Stimulation™ (NPS™) technology, announced today two changes to its current rights offering.
-
Pulse Biosciences Reports First Quarter 2022 Financial Results
5/11/2022
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced financial results for the first quarter of 2022.
-
Pulse Biosciences, Inc. Announces Commencement of Rights Offering - May 04, 2022
5/4/2022
Pulse Biosciences, Inc., a novel bioelectric medicine company, announced that it has commenced its previously announced rights offering of up to $15,000,000 of units at the Initial Price.
-
Pulse Biosciences Schedules First Quarter 2022 Financial Results Conference Call for May 11, 2022
4/28/2022
Pulse Biosciences, Inc. announced today it will report financial results for the first quarter of 2022 after market close on Wednesday, May 11, 2022. Company management will host a corresponding conference call beginning at 1:30pm PT.
-
Pulse Biosciences to Present New Data on Nano-Pulse Stimulation Procedure for Sebaceous Hyperplasia and for Focal Epithelial Hyperplasia at 2022 American Society of Laser Medicine and Surgery Annual Conference
4/26/2022
Pulse Biosciences, Inc today announced that one oral presentation and one poster presentation on the results of performing the CellFX procedure for lesion clearance will be delivered at the 2022 American Society for Laser Medicine and Surgery (ASLMS) Annual Meeting, taking place on April 27-30, 2022 in San Diego, California.
-
Pulse Biosciences, Inc. Announces Rights Offering - Apr 14, 2022
4/14/2022
Pulse Biosciences, Inc., a novel bioelectric medicine company, announced that the Company’s Board of Directors has approved a rights offering available to all holders of record of the Company’s common stock, par value $0.001 per share as of the close of market on April 25, 2022.